HDL结合的miR-181c-5p升高与澳大利亚原住民糖尿病血管并发症相关
本研究比较澳大利亚原住民无糖尿病、2型糖尿病及糖尿病大血管并发症三组HDL中miRNA表达与促血管生成功能。结果发现并发症组HDL的miR-181c-5p水平较健康组和T2DM组高14倍,且与疾病严重程度正相关;该组HDL促内皮成管能力受损,伴细胞miR-181c-5p升高。提示HDL-miRNA谱或可辅助判断糖尿病血管并发症严重程度。
要点
- 糖尿病并发症组HDL中抗血管生成miR-181c-5p较健康组和T2DM组高14倍。
- HDL-miR-181c-5p水平与疾病严重程度正相关(p=0.0020)。
- 并发症组HDL促内皮成管能力受损,伴细胞miR-181c-5p升高。
核心结论
- 澳大利亚原住民糖尿病并发症患者的HDL促血管生成能力降低。
- 该损伤与抗血管生成miR-181c-5p表达升高相关。
研究设计与样本
- 从原住民参与者血浆分离HDL,分无糖尿病(Healthy)、T2DM、T2DM+大血管并发症(T2DM+Comp)三组。
- 用人冠状动脉内皮细胞在高糖(25 mmol/l)下处理PBS、rHDL或分离HDL,qPCR测miRNA,Matrigel成管实验评估血管生成。
主要发现
- 并发症组HDL的miR-181c-5p为1454 ± 1346%,高于Healthy组100 ± 121%(p < 0.05)和T2DM组82 ± 77%(p < 0.05)。
- HDL相关miR-181c-5p与疾病严重程度正相关(p = 0.0020)。
- 高糖下rHDL、Healthy HDL、T2DM HDL处理组小管数增加(rHDL 136 ± 8%,p < 0.01;Healthy 128 ± 6%,p < 0.01;T2DM 124 ± 5%,p < 0.05),分支点亦增加。
- T2DM+Comp HDL组小管数113 ± 6%(p = 0.32)、分支点113 ± 5%(p = 0.28)、HIF1A 117 ± 6%(p = 0.43),促血管生成增加未出现。
- T2DM+Comp HDL处理细胞miR-181c-5p为136 ± 7%,高于PBS 100 ± 9%(p < 0.05)。
临床怎么用
- HDL-miRNA谱有望辅助临床判断原住民糖尿病血管并发症严重程度。
- 靶向HDL-miRNA的个体化干预或可预防或逆转糖尿病血管并发症。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Diabetes is a major burden on Australia's Indigenous population, with high rates of disease and vascular complications. Diabetic vascular complications are associated with impaired ischaemia-driven angiogenesis. MicroRNAs (miRNAs) are key players in the regulation of angiogenesis. HDL-cholesterol (HDL-c) levels are inversely associated with the risk of developing diabetic complications and HDL can carry miRNAs. HDL-miRNA profiles differ in disease states and may present as biomarkers with the capacity to act as bioactive signalling molecules. Recent studies have demonstrated that HDL becomes dysfunctional in a diabetic environment, losing its vasculo-protective effects and becoming more pro-atherogenic. We sought to determine whether HDL-associated miRNA profiles and HDL functionality were predictive of the severity of diabetic vascular complications in Australia's Indigenous population. METHODS: HDL was isolated from plasma samples from Indigenous participants without diabetes ('Healthy'), with type 2 diabetes mellitus ('T2DM') and with diabetes-associated macrovascular complications (specifically peripheral artery disease, 'T2DM+Comp'). To assess HDL angiogenic capacity, human coronary artery endothelial cells were treated with PBS, reconstituted HDL (rHDL, positive control) or isolated HDL and then exposed to high-glucose (25 mmol/l) conditions. The expression levels of two anti-angiogenic miRNAs (miR-181c-5p and miR-223-3p) and one pro-angiogenic miRNA (miR-27b-3p) were measured in the HDL fraction, plasma and treated human coronary artery endothelial cells by quantitative real-time PCR. In vitro endothelial tubule formation was assessed using the Matrigel tubulogenesis assay. RESULTS: Strikingly, we found that the levels of the anti-angiogenic miRNA miR-181c-5p were 14-fold higher (1454 ± 1346%) in the HDL from Aboriginal people with diabetic complications compared with both the Healthy (100 ± 121%, p < 0.05) and T2DM (82 ± 77%, p < 0.05) groups. Interestingly, we observed a positive correlation between HDL-associated miR-181c-5p levels and disease severity (p = 0.0020). Under high-glucose conditions, cells treated with rHDL, Healthy HDL and T2DM HDL had increased numbers of tubules (rHDL: 136 ± 8%, p < 0.01; Healthy HDL: 128 ± 6%, p < 0.01; T2DM HDL: 124 ± 5%, p < 0.05) and branch points (rHDL: 138 ± 8%, p < 0.001; Healthy HDL: 128 ± 6%, p < 0.01; T2DM HDL: 127 ± 5%, p < 0.01) concomitant with elevations in mRNA levels of the key hypoxia angiogenic transcription factor HIF1A (rHDL: 140 ± 10%, p < 0.01; Healthy HDL: 136 ± 8%, p < 0.01; T2DM HDL: 133 ± 9%, p < 0.05). However, this increase in angiogenic capacity was not observed in cells treated with T2DM + Comp HDL (tubule numbers: 113 ± 6%, p = 0.32; branch points: 113 ± 5%, p = 0.28; HIF1A: 117 ± 6%, p = 0.43), which could be attributed to the increase in cellular miR-181c-5p levels (T2DM + Comp HDL: 136 ± 7% vs PBS: 100 ± 9%, p < 0.05). CONCLUSIONS/INTERPRETATION: In conclusion, HDL from Aboriginal people with diabetic complications had reduced angiogenic capacity. This impairment is associated with an increase in the expression of anti-angiogenic miR-181c-5p. These findings provide the rationale for a new way to better inform clinical diagnosis of disease severity with the potential to incorporate targeted, personalised HDL-miRNA intervention therapies to prevent further development of, or to reverse, diabetic vascular complications in Australian Aboriginal people.
引用
- Morrison KR, Solly EL, Shemesh T, et al. Elevated HDL-bound miR-181c-5p level is associated with diabetic vascular complications in Australian Aboriginal people. Diabetologia. 2021. PMID: 33651121. doi:10.1007/s00125-021-05414-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。